Cargando…
S212: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428257/ http://dx.doi.org/10.1097/01.HS9.0000967760.70775.53 |
| _version_ | 1785090424310857728 |
|---|---|
| author | Zhang, Yi Zhou, Hu Zhuang, Junling He, Aili LI, Yarong Yang, Linhua Du, Xin Gao, Sujun He, Guangsheng Hong, Mei Jiang, Qian Jiang, Zhongxing Kai, Sun Yue, Lingling Zheng, Cuiping Zhou, Zeping Jin, Chenghao Jing, Hongmei Liu, Lin Liu, Qingchi Wang, Jishi Wu, Wen Xu, Yajing Wu, Dengshu Xu, Na Zhang, Feng Zhang, Jin Zhu, Huanling Xiao, Zhijian Jin, Jie |
| author_facet | Zhang, Yi Zhou, Hu Zhuang, Junling He, Aili LI, Yarong Yang, Linhua Du, Xin Gao, Sujun He, Guangsheng Hong, Mei Jiang, Qian Jiang, Zhongxing Kai, Sun Yue, Lingling Zheng, Cuiping Zhou, Zeping Jin, Chenghao Jing, Hongmei Liu, Lin Liu, Qingchi Wang, Jishi Wu, Wen Xu, Yajing Wu, Dengshu Xu, Na Zhang, Feng Zhang, Jin Zhu, Huanling Xiao, Zhijian Jin, Jie |
| author_sort | Zhang, Yi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428257 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104282572023-08-17 S212: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS Zhang, Yi Zhou, Hu Zhuang, Junling He, Aili LI, Yarong Yang, Linhua Du, Xin Gao, Sujun He, Guangsheng Hong, Mei Jiang, Qian Jiang, Zhongxing Kai, Sun Yue, Lingling Zheng, Cuiping Zhou, Zeping Jin, Chenghao Jing, Hongmei Liu, Lin Liu, Qingchi Wang, Jishi Wu, Wen Xu, Yajing Wu, Dengshu Xu, Na Zhang, Feng Zhang, Jin Zhu, Huanling Xiao, Zhijian Jin, Jie Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428257/ http://dx.doi.org/10.1097/01.HS9.0000967760.70775.53 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Sessions Zhang, Yi Zhou, Hu Zhuang, Junling He, Aili LI, Yarong Yang, Linhua Du, Xin Gao, Sujun He, Guangsheng Hong, Mei Jiang, Qian Jiang, Zhongxing Kai, Sun Yue, Lingling Zheng, Cuiping Zhou, Zeping Jin, Chenghao Jing, Hongmei Liu, Lin Liu, Qingchi Wang, Jishi Wu, Wen Xu, Yajing Wu, Dengshu Xu, Na Zhang, Feng Zhang, Jin Zhu, Huanling Xiao, Zhijian Jin, Jie S212: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS |
| title | S212: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS |
| title_full | S212: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS |
| title_fullStr | S212: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS |
| title_full_unstemmed | S212: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS |
| title_short | S212: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS |
| title_sort | s212: a randomized double-blind phase 3 study of jaktinib versus hydroxyurea in patients with intermediate-2 or high risk myelofibrosis |
| topic | Oral Sessions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428257/ http://dx.doi.org/10.1097/01.HS9.0000967760.70775.53 |
| work_keys_str_mv | AT zhangyi s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT zhouhu s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT zhuangjunling s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT heaili s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT liyarong s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT yanglinhua s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT duxin s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT gaosujun s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT heguangsheng s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT hongmei s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT jiangqian s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT jiangzhongxing s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT kaisun s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT yuelingling s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT zhengcuiping s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT zhouzeping s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT jinchenghao s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT jinghongmei s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT liulin s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT liuqingchi s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT wangjishi s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT wuwen s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT xuyajing s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT wudengshu s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT xuna s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT zhangfeng s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT zhangjin s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT zhuhuanling s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT xiaozhijian s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT jinjie s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis |